Bioversys Ag

Eth Zurich

Swissgenetics

Christian Kemmer

Peter Schneider

Glenn E Dale

Marc Gitzinger

Sergio Lociuro

Marilyne Bourotte

Vincent Trebosc

Martin Fussenegger

Wilfried Weber

David Fluri

Ulrich Witschi

Michel Pieren

Birgit Schellhorn

Julian Schill

The invention provides antibiotic combination therapies for treating aninfection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Antibiotic combination therapies

The invention provides systems and methods for increased clinical efficacy of rifabutin against. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin intocells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection ofin the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or C. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cis that greater than about 2 mg/L and optionally less than about 50 mg/L.

Rifabutin treatment methods, uses, and compositions

The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm.

Degradable microcapsules

Growing community of inventors

Riehen, Switzerland

Christian Kemmer